First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors

By: via Benzinga
Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.